Skip to main content
QNTM
NASDAQ Life Sciences

Quantum Biopharma Secures Cash Runway to 2028, Maintains 'No Going Concern' Status

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$3.79
Mkt Cap
$15.771M
52W Low
$2.07
52W High
$38.25
52W Position info
83% above low
Off High info
90% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

QNTM sits 83% above its 52-week low of $2.07.

Summary

Quantum Biopharma reported audited 2025 financial results, confirming a cash runway through January 2028 with $11.3 million in cash and digital assets, and maintaining a 'No Going Concern' status.


Key Events · Financing and Capital Events · QNTM

  • Financial Stability Confirmed

    The company maintains a 'No Going Concern' status and reports $11.3 million in cash and digital assets, providing a cash runway through January 2028. This significantly improves the financial outlook compared to the recent 20-F filing.

  • Operational Efficiency

    Operating expenses, R&D fees, and General & Administrative expenses were reduced in 2025, with trade and other payables cut by approximately 50% from $4.1 million to $2.0 million since year-end.

  • Product Development Progress

    Positive results from the unbuzzd dietary supplement clinical trial were published in a peer-reviewed journal. The Lucid-MS drug candidate completed Phase 1 oral toxicity studies with no issues and is advancing towards a Phase 2 IND filing in H1 2026.

  • Board Resignation

    Terry Lynch resigned from the board of directors effective March 27, 2026, citing constraints on his ability to dedicate adequate time to the company.


Analysis · QNTM · Life Sciences

This filing provides a critical update on Quantum Biopharma's financial health, directly addressing concerns that might have arisen from the recent 20-F annual report. The company's ability to extend its cash runway to January 2028 with $11.3 million in cash and digital assets, representing a substantial portion of its market capitalization, significantly de-risks its near-term operations. The reported reductions in operating expenses, R&D, G&A, and trade payables further strengthen the balance sheet. Positive updates on the unbuzzd clinical trial and Lucid-MS drug candidate's progression to Phase 2, along with the unbuzzd IPO plans, provide additional operational momentum. Investors should view this as a strong positive signal for the company's stability and future development.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QNTM was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.8M. The 52-week trading range was $2.07 to $38.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QNTM - Latest Insights

QNTM
Nov 12, 2026, 4:06 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.78
Real-time Price: $1.60 info
Change: -$0.180 (-10%) info
Market Cap: $13.021M info
QNTM
Nov 12, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.60 info
Change: -$0.400 (-20%) info
Market Cap: $13.021M info
QNTM
Oct 08, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.09
Real-time Price: $1.60 info
Change: -$1.49 (-48%) info
Market Cap: $13.021M info
QNTM
Oct 06, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.27
Real-time Price: $1.60 info
Change: -$1.67 (-51%) info
Market Cap: $13.021M info
QNTM
Sep 01, 2026, 8:28 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.02
Real-time Price: $1.60 info
Change: -$1.42 (-47%) info
Market Cap: $13.021M info